

REMARKS/ARGUMENTS

It is submitted that the CPA application, filed on August 13, 2001, in view of the subject Amendment, complies with 37 CFR 1.121(c)(1)(ii), by the submitting herein of a clean version of the amended claims 69, 71, 72, and 75-80 as item 1.

It is further submitted that the CPA application, filed on August 13, 2001, complied with 37 CFR 1.121(c)(1) (ii) in submitting a marked-up version of the amended claims. The marked-up version of the amended claims 69, 71, 72, and 75-80 is included herein as item 3.

In sum, it is submitted that claims 69-83, which remain under consideration, should now be found to be in condition for allowance.

It is noted that claims 1-68 and 84-87 have been withdrawn from consideration.

3. VERSION WITH MARKINGS TO SHOW CHANGES MADE TO CLAIMS UNDER
37 CFR 1.121(b)(1) (iii) FILED ON AUGUST 13, 2001

69. (four times amended) A therapeutic agent being a soluble precipitable material which is to be converted into an insoluble and non-digestible precipitate by the action of a non-mammalian enzyme when the therapeutic agent is administered to a living host containing a heterogeneous population of cancer cells, the heterogeneous population of cancer cells including at least a sub-population of cancer cells being the target cancer cells, each including a first antigenic receptor, the therapeutic agent being adjacent to the target cancer cells subsequent to the administration to the living host of a bispecific reagent, the bispecific reagent when administered to a living host being bound to the target cancer cells, the bispecific reagent containing two moieties, a first moiety which is a non-mammalian enzyme moiety being a first enzyme moiety, the bispecific reagent further containing a second moiety including a targeting agent moiety which has a substantial affinity for the first antigenic receptor of the target cancer cells, the therapeutic agent to be converted in the extra-cellular fluid of the living host, adjacent to the bispecific reagent, into an insoluble and non-digestible precipitate which is an extra-cellular precipitate by the action of the first enzyme moiety of the bispecific reagent, the bispecific reagent to be bound to the target cancer cells, the therapeutic agent being from a group consisting of peptides, including opio-melanins, of carbohydrates, including cellulose, chitosan, and chitin, of proteoglycans, of synthetic polymers, and of indoxyl compounds containing molecular positions 1-7, the extra-cellular precipitate having an epitope selected from the group consisting of a first antigenic epitope, being an epitope which is an integral part of the structure of the extra-cellular precipitate, a second antigenic epitope, and a neo-antigenic third epitope; the non-antigenic third epitope not being present on the therapeutic agent, the extra-cellular precipitate remaining in the extra-cellular fluid adjacent to the bispecific reagent [for an extended period of time].

71. (three times amended) A therapeutic agent in accordance with claim 69 in which a cell-impermeant [molecule] material is attached to the therapeutic agent, the cell-impermeant [molecule] material causing the therapeutic agent to be cell impermeant.

72. (four times amended) A therapeutic agent in accordance with claim 71 in which the cell-impermeant [molecules] material is selected from the group consisting of thiol, anionic materials, and [molecules] material of a molecular weight greater than 1000 daltons.

75. (three times amended) A therapeutic agent in accordance with claim 74 in which the soluble intermediate molecule having the characteristic to be oxidized in the natural environment within the extra-cellular fluid, the oxidized soluble intermediate molecule being spontaneously dimerized, thereby forming the extra-cellular precipitate.

76. (four times amended) A therapeutic agent in accordance with claim 69 in which each of the indoxyl compounds is selected from the group consisting of indoxyl-lactam and indoxyl-glycosides, which when attached to position 3 of the indoxyl compounds are cleavable by the first enzyme moiety of the bispecific reagent, the material remaining after cleaving at position 3 being a soluble reactive intermediate molecule which can be oxidized and dimerized, thereby forming the extra-cellular precipitate.

77. (three times amended) A therapeutic agent in accordance with claim 69 in which each of the indoxyl compounds can when attached to at least one of positions 4, 5, 6, and 7 of the indoxyl compound to [reduce the ability of the indoxyl compounds and the extra-cellular precipitate to] move [by at least one of diffusion and convective flow] in the extracellular fluid.

78. (three times amended) A therapeutic agent in accordance with claim 69 in which each of the indoxyl compounds includes phenyl compounds attached at position 5 of the indoxyl compound to {reduce the ability of the indoxyl compounds and the extra-cellular precipitate to} move [by at least one of diffusion and convective flow] in the extracellular fluid.

79. (three times amended) A therapeutic agent in accordance with claim 69 in which each of the indoxyl compounds includes benzyloxy compounds attached at position 5 of the indoxyl compounds to reduce the ability of the indoxyl compounds and the extra-cellular precipitate to move [by at least one of diffusion and convective flow] in the extracellular fluid.

80. (twice amended) A therapeutic agent in accordance with claim 69 in which each of the indoxyl compounds includes 5,5-bi-indoxyls attached at position 5 of the indoxyl compounds to reduce the ability of the indoxyl compounds and the extra-cellular precipitate to move by at least one of diffusion and convective flow in the extracellular fluid.

Favorable action is solicited.

Respectfully submitted,

John Q. McQuillan

John Q. McQuillan
Reg. No. 19,805

Dated: November 13, 2001